Literature DB >> 23940449

Functions of cyclophilin A in atherosclerosis.

Zhang Tian-Tian1, Zhang Jun-Feng, Ge Heng.   

Abstract

Cyclophilin A (CypA) is a ubiquitously distributed protein present both in intracellular and extracellular spaces. In atherosclerosis, various cells, including endothelial cells, monocytes, vascular smooth muscle cells and platelets, secrete CypA in response to excessive levels of reactive oxygen species. Atherosclerosis, a complicated disease, is the result of the interplay of different risk factors. Researchers have found that CypA links many risk factors, including hyperlipidemia, hypertension and diabetes, to atherosclerosis that develop into a vicious cycle. Furthermore, most studies have shown that secreted CypA participates in the developmental process of atherosclerosis via many important intracellular mechanisms. CypA can cause injury to and apoptosis of endothelial cells, leading to dysfunction of the endothelium. CypA may also induce the activation and migration of leukocytes, producing proinflammatory cytokines that promote inflammation in blood vessels. In addition, CypA can promote the proliferation of monocytes/macrophages and vascular smooth muscle cells, leading to the formation of foam cells and the remodelling of the vascular wall. Studies investigating the roles of CypA in atherosclerosis may provide new direction for preventive and interventional treatment strategies in atherosclerosis.

Entities:  

Keywords:  Atherosclerosis; CD147; Cyclophilin A

Year:  2013        PMID: 23940449      PMCID: PMC3718612     

Source DB:  PubMed          Journal:  Exp Clin Cardiol        ISSN: 1205-6626


  60 in total

1.  Extracellular cyclophilins contribute to the regulation of inflammatory responses.

Authors:  Kamalpreet Arora; William M Gwinn; Molly A Bower; Alan Watson; Ifeanyi Okwumabua; H Robson MacDonald; Michael I Bukrinsky; Stephanie L Constant
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

Review 2.  Cytokines in atherosclerosis: pathogenic and regulatory pathways.

Authors:  Alain Tedgui; Ziad Mallat
Journal:  Physiol Rev       Date:  2006-04       Impact factor: 37.312

Review 3.  An overview of cyclophilins in human cancers.

Authors:  J Lee; S S Kim
Journal:  J Int Med Res       Date:  2010 Sep-Oct       Impact factor: 1.671

4.  TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS.

Authors:  Stefanie Zeuke; Artur J Ulmer; Shoichi Kusumoto; Hugo A Katus; Holger Heine
Journal:  Cardiovasc Res       Date:  2002-10       Impact factor: 10.787

5.  A selective estrogen receptor modulator inhibits TNF-alpha-induced apoptosis by activating ERK1/2 signaling pathway in vascular endothelial cells.

Authors:  Jing Yu; Masato Eto; Masahiro Akishita; Tetsuro Okabe; Yasuyoshi Ouchi
Journal:  Vascul Pharmacol       Date:  2009-01-25       Impact factor: 5.773

6.  Cyclophilin A functions as an endogenous inhibitor for membrane-bound guanylate cyclase-A.

Authors:  Zi-Jiang Chen; Michael Vetter; Geen-Dong Chang; Shiguo Liu; Danian Che; Yaxian Ding; Sung Soo Kim; Chung-Ho Chang
Journal:  Hypertension       Date:  2004-10-04       Impact factor: 10.190

7.  Extracellular matrix metalloproteinase inducer (CD147) is a novel receptor on platelets, activates platelets, and augments nuclear factor kappaB-dependent inflammation in monocytes.

Authors:  Roland Schmidt; Andreas Bültmann; Sina Fischel; Angelika Gillitzer; Paul Cullen; Axel Walch; Philipp Jost; Martin Ungerer; Neal D Tolley; Stephan Lindemann; Meinrad Gawaz; Albert Schömig; Andreas E May
Journal:  Circ Res       Date:  2007-11-29       Impact factor: 17.367

8.  A search for cyclophilin-A gene (PPIA) variation and its contribution to the risk of atherosclerosis and myocardial infarction.

Authors:  M Palacín; I Rodríguez; M García-Castro; F Ortega; J R Reguero; C López-Larrea; C Morís; V Alvarez; E Coto
Journal:  Int J Immunogenet       Date:  2008-04       Impact factor: 1.466

9.  Cyclophilin A enhances vascular oxidative stress and the development of angiotensin II-induced aortic aneurysms.

Authors:  Kimio Satoh; Patrizia Nigro; Tetsuya Matoba; Michael R O'Dell; Zhaoqiang Cui; Xi Shi; Amy Mohan; Chen Yan; Jun-ichi Abe; Karl A Illig; Bradford C Berk
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

Review 10.  Dealing with the family: CD147 interactions with cyclophilins.

Authors:  Vyacheslav Yurchenko; Stephanie Constant; Michael Bukrinsky
Journal:  Immunology       Date:  2006-03       Impact factor: 7.397

View more
  5 in total

Review 1.  The roles of CD147 and/or cyclophilin A in kidney diseases.

Authors:  Xin Qu; Chunting Wang; Jicheng Zhang; Guoqiang Qie; Jianxin Zhou
Journal:  Mediators Inflamm       Date:  2014-12-17       Impact factor: 4.711

2.  Cyclophilin A enhances macrophage differentiation and lipid uptake in high glucose conditions: a cellular mechanism for accelerated macro vascular disease in diabetes mellitus.

Authors:  Surya Ramachandran; Anandan Vinitha; Cheranellore Chandrasekharan Kartha
Journal:  Cardiovasc Diabetol       Date:  2016-11-03       Impact factor: 9.951

3.  A Pan-Cyclophilin Inhibitor, CRV431, Decreases Fibrosis and Tumor Development in Chronic Liver Disease Models.

Authors:  Joseph Kuo; Michael Bobardt; Udayan Chatterji; Patrick R Mayo; Daniel J Trepanier; Robert T Foster; Philippe Gallay; Daren R Ure
Journal:  J Pharmacol Exp Ther       Date:  2019-08-12       Impact factor: 4.030

4.  Cyclophilin A (CypA) Plays Dual Roles in Regulation of Bone Anabolism and Resorption.

Authors:  Mian Guo; Aaron W James; Jin Hee Kwak; Jia Shen; Kazunari K Yokoyama; Kang Ting; Chia B Soo; Robert H Chiu
Journal:  Sci Rep       Date:  2016-03-02       Impact factor: 4.379

5.  Cyclophilin A Impairs Efferocytosis and Accelerates Atherosclerosis by Overexpressing CD 47 and Down-Regulating Calreticulin.

Authors:  Vinitha Anandan; Thushara Thulaseedharan; Aishwarya Suresh Kumar; Karthika Chandran Latha; Amjesh Revikumar; Ajit Mullasari; Chandrasekharan C Kartha; Abdul Jaleel; Surya Ramachandran
Journal:  Cells       Date:  2021-12-20       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.